Treatment with paritaprevir/ritonavir/ombitasvir and dasabuvir with ribavirin for 8 weeks is highly effective for patients with recent hepatitis C (HCV) infection, regardless of HIV status, according to results published in the Journal of Viral Hepatology. Furthermore, no virological failure or posttreatment relapse was observed during this trial with this shortened therapy regimen.
The study included participants with recent HCV (duration of infection <12 months, n=30) who received paritaprevir/ritonavir/ombitasvir and dasabuvir (with weight-based ribavirin for genotype 1a and 1) for 8 weeks. Of the 30 participants, 77% (n=23) were HIV-positive.
The primary endpoint was sustained virologic response at 12 weeks posttreatment (SVR12).
After 12 weeks posttreatment, 97% (n=29) participants achieved SVR12. One participant had discontinued treatment early, at week 2, after hospitalization for an unrelated adverse event.
Among participants with HIV coinfection, SVR12 was 100% (23/23; 95% CI, 85%-100%). Among participants with HCV monoinfection, SVR12 was 86% (6/7; 95% CI, 42%-100%; per protocol, 100%, 6/6).
The results indicated that high baseline HCV RNA did not affect treatment efficacy, with SVR12 100% (13/13; 95% CI 75%-100%) among participants with baseline HCV RNA >6 log10 IU/mL, including 5 participants with baseline HCV RNA >7 log10 IU/mL.
This study was funded in part by AbbVie Inc.
Martinello M, Bhagani S, Gane E, et al. Shortened therapy of eight weeks with paritaprevir/ritonavir/ombitasvir and dasabuvir is highly effective in people with recent HCV genotype 1 infection [published online April 16, 2018]. J Viral Hepat. doi: 10.1111/jvh.12917